Keros Therapeutics Inc <KROS.O>: Leerink Partners cuts target price to $23 from $30
KROS•Related News
Shoals Q2 FY26 net income falls 12.39% to $12.1 million; revenue rises 47.4% to $163.4 million
SHLS•
V2X Inc <VVX.N>: Truist Securities raises target price to $85 from $70
VVX•
BlackRock trims SAP stake to 6.74% from 6.75%
SAP•
Main Street Capital declares USD 0.265 monthly dividend for Oct-Dec 2026
MAIN•
Everspin, MaxLinear sign MOU to evaluate next-generation memory architectures for AI servers
MRAM•